Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

Inclusion Criteria:

• laboratory confirmed positive test for SARS-CoV-2
• admitted to ICU because of critical illness due to covid-19

Exclusion Criteria:

• patients with treatment for thromboembolic complications at arrival to the ICU
• short ICU length of stay defined as discharged the same or the following day as ICU admission